I

Integer Holdings Corporation

Medical device CDMO for cardiac devices

Trade Compliance Specialist - Vuce & Siga

Full-TimeUpdated on 10/23/2026
No salary listed
Mid, Senior
Bachelor's
Santo Domingo, Dominican Republic
In Person
Risk & ComplianceRegulatory Compliance & Ethics

About the job

Requirements
  • A degree in International Business, Foreign Trade, or a related field is required.
  • At least 3 to 5 years of experience in the same or a similar position is required.
  • Knowledge of customs compliance requirements in the United States and the Dominican Republic is required.
  • Knowledge of tariff classification in the United States and the Dominican Republic is required.
  • Knowledge of the National Council of Free Trade Zones and the Directorate General of Customs regulations is required.
  • Knowledge of permits for companies in Free Trade Zones and import/export permit submissions and renewals through VUCE is required.
  • Knowledge of government procedures involving agencies such as the Ministry of Environment and the Ministry of Health is required.
  • Knowledge of import and export Certificates of Origin is required.
  • Knowledge of the DR-CAFTA agreement between the Dominican Republic and the United States and analysis of finished products is required.
  • Knowledge of country-of-origin marking, Binding Rulings, and programs 9801 and 9802 is required.
  • Knowledge of FDA regulations for medical devices and U.S. customs duties is required.
  • Knowledge of Authorized Economic Operator certification is required.
  • Knowledge of an ERP system and Annex 24 software such as Intrade, Zoe, or I-Xport is required.
  • Knowledge of Microsoft Office and Oracle is required.
  • Intermediate or advanced English is required.
  • Negotiation, organization, personnel management, and time-management skills are required.
Responsibilities
  • Develop and implement policies and procedures to ensure compliance with import and export regulations.
  • Lead internal and external audits and audits conducted by authorities.
  • Manage permits for companies in Free Trade Zones.
  • Submit import and export permits and renewals through VUCE.
  • Prepare procedures with government agencies, including the Ministry of Environment and the Ministry of Health.
  • Prepare Certificates of Origin for imports and exports and for finished products under the DR-CAFTA agreement.
  • Register new products.
  • Monitor and measure the company’s customs compliance performance and manage key performance indicators.
  • Attend government visits in the Dominican Republic.
  • Ensure accurate maintenance of import and export records.
  • Work with supply chain and logistics to identify and manage cost-saving opportunities.

About the company

I

Integer Holdings Corporation

View

Integer Holdings Corporation is a large medical device contract development and manufacturing organization (CDMO) that supports medical device makers in cardiac rhythm management, neuromodulation, and cardiovascular markets. It provides end-to-end services from design support to manufacturing, delivering components and finished subsystems such as implants, housings, electrodes, and batteries through its Greatbatch Medical, Lake Region Medical, and Electrochem brands. The company differentiates itself by its scale, breadth of capabilities across multiple medical specialties, established brand portfolio, and global manufacturing footprint that enable reliable, integrated supply. Its goal is to improve patients’ lives worldwide by helping customers bring safe and effective medical technologies to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Wilmington, Delaware

Founded

1940

Get referred to Integer Holdings Corporation

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $464.1 million, beating estimates despite weak medtech demand.
  • Integer expects demand recovery after New Ross's July 27-August 10, 2026 shutdown.
  • KKR plans new capacity, technology, and employee ownership after closing by year-end 2026.

What critics are saying

  • Integer withdrew 2026 guidance on August 3, 2026, after KKR announced the buyout.
  • Schall, Brown & Schwartz opened an August 23, 2026 fiduciary-duty investigation.
  • Regulatory or stockholder rejection kills the KKR deal and leaves Integer's weak standalone outlook exposed.

What makes Integer Holdings Corporation unique

  • Integer's R&D Velocity integrates design, prototyping, and manufacturing for complex medtech programs.
  • Its 33-facility global network spans electrophysiology, neuromodulation, and structural heart.
  • KKR's August 3, 2026, $5.7 billion bid validates Integer's scale and customer lock-in.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Adoption Assistance
  • Parental Leave
  • 401(k) Company Match
  • 401(k) Retirement Plan
  • Paid Vacation
  • Paid Holidays

Growth & Insights and Company News

6 month growth

0%

1 year growth

-2%

2 year growth

-1%
Ticker Report
Aug 29th, 2026
Boussard & Gavaudan Gestion Sas Makes New $2.60 Million Investment in Integer Holdings Corporation $ITGR

Boussard & Gavaudan Gestion Sas bought a new position in Integer Holdings Corporation (NYSE:ITGR – Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 28,153 shares of the medical equipment provider’s stock, valued at approximately $2,597,000. Other institutional investors and hedge funds also […]

Yahoo Finance
Aug 16th, 2026
Healthcare stocks outpace S&P 500 by 13 percentage points over six months

Healthcare stocks have returned 26.1% over the past six months, outperforming the S&P 500 by 13.1 percentage points. However, investors must remain cautious due to heavy regulation affecting earnings potential. Integer Holdings faces concerns with 6.1% annual revenue growth over two years, lagging healthcare peers. Its modest revenue base of $1.84 billion provides less fixed cost leverage than larger competitors. The company trades at $125.07 per share, or 18.6 times forward price-to-earnings. Evolent Health shows weak platform performance and declining returns on capital. Its high net-debt-to-EBITDA ratio of 7 times could force unfavourable capital raises if market conditions worsen. Shares trade at $4.15, representing 12.4 times forward price-to-earnings. Tenet Healthcare, operating hospitals and surgical centres across nine US states, emerges as the recommended healthcare investment.

Yahoo Finance
Aug 4th, 2026
Integer Holdings acquired by KKR for $5.7B in all-cash deal at $127 per share

Integer Holdings agreed to be acquired by private equity firm KKR in an all-cash deal valued at approximately $5.7 billion. The transaction values the medical technology company at $127 per share. Shares jumped 2.7% in afternoon trading, continuing a rally from the previous session when the stock surged over 20% following the announcement. The acquisition news overshadowed strong second-quarter results, where Integer posted an adjusted profit of $1.60 per share on $464.1 million in revenue, surpassing analyst estimates. Following the buyout announcement, Integer withdrew its previously issued financial guidance and cancelled its upcoming earnings conference call. Shares traded at $124.50, marking a new 52-week high.

BizWire Express
Aug 3rd, 2026
KKR to acquire Integer for $5.7B in all-cash deal at $127 per share

KKR has agreed to acquire Integer Holdings Corporation, a medical device contract development and manufacturing organisation, in an all-cash transaction valued at approximately $5.7 billion. Integer stockholders will receive $127 per share, representing a 51.8% premium to the company's closing share price on 29 April 2026. The acquisition follows a comprehensive strategic review announced by Integer in April 2026. The Integer Board unanimously approved the agreement and recommends stockholder approval. KKR plans to invest in Integer's capacity, technology, innovation, and talent. The firm also intends to establish a broad-based employee ownership programme following the transaction's close, consistent with its approach across portfolio companies. The transaction is expected to close by year-end, subject to stockholder approval and regulatory clearances. Upon completion, Integer will become privately held and delist from the New York Stock Exchange.

Yahoo Finance
Aug 3rd, 2026
Integer Holdings beats Q2 expectations with $464M revenue and $1.60 earnings per share

Integer Holdings Corp. reported second-quarter net income of $23.6 million, or 69 cents per share. Adjusted earnings came to $1.60 per share, exceeding Wall Street expectations of $1.38 per share. The Plano, Texas-based medical device outsource manufacturer posted revenue of $464.1 million for the period, also beating analyst forecasts of $452.5 million. The results surpassed predictions from five analysts surveyed by Zacks Investment Research on both earnings and revenue metrics.